Literature DB >> 28876537

Steroid phobia, Chinese medicine and asthma control.

Ka Ian Ip1, Kam Lun Hon2, Kathy Yin Ching Tsang3, Theresa Ngan Ho Leung1,4.   

Abstract

BACKGROUND: Inhaled corticosteroids (ICS) are the mainstay of treatment for asthma. Corticosteroid (CS) phobia and fears are prevalent, and these may influence therapeutic efficacy and asthma control. AIM: The aim of this study was to evaluate if CS fear is associated with asthma control in children.
METHODS: Patients aged >4 years with asthma at a pediatric outpatient clinic were surveyed, and the Asthma Control Test (ACT) was used for the assessment of asthma control.
RESULTS: Ninety-eight patients and their parents were interviewed. Thirty-four (35%) parents reported moderate or significant CS fear. They were more likely than those with no or little fear to have poorer asthma control (mean ACT scores 21.3 ± 4.0 vs 23.1 ± 3.3, P = 0.02), discuss their fears with their doctors (P < 0.001), request CS sparing medications (P = 0.044) and resort to Chinese medicine (CM) usage (P < 0.001). Backward binomial logistic regression showed parents with moderate/significant fears were more likely to discuss their fears with their doctors (OR: 5.21; 95% CI: 1.86-14.59; P = 0.002) and have used CM (OR: 4.28; 95% CI: 1.61-11.41; P = 0.004). CS fear was not translated to reduced self-reported compliance in the prescribed ICS. About 40% of the respondents had ever used Chinese Medicine (CM) with 82% of the users reported having used Chinese herbal medicine and 49% had used cold moxibustion.
CONCLUSIONS: CS fear and CM usage are prevalent. Parents with CS fear were more likely to have children with poorer asthma control and have used Chinese medicine. Physicians caring for children with asthma should be aware of parents with CS fear, prepared to address the fear or concerns and offer evidence-based alternative treatment.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  Chinese medicine; asthma control; corticosteroid fears

Mesh:

Substances:

Year:  2017        PMID: 28876537     DOI: 10.1111/crj.12705

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  6 in total

1.  Clinical Efficacy of Sanfeng Tongqiao Diwan in the Treatment of Allergic Rhinitis: A Randomized Controlled Trial.

Authors:  Jing Ma; Jiaying Luo; Zhangkai Cheng; Gui Chen; Zhiman Liang; Baoqing Sun; Feng Wang
Journal:  Dis Markers       Date:  2022-06-25       Impact factor: 3.464

2.  Adherence to therapy regimen by children with asthma and their parents.

Authors:  Alina Trojanowska; Andrzej Emeryk; Danuta Zarzycka
Journal:  Postepy Dermatol Alergol       Date:  2022-05-09       Impact factor: 1.664

3.  Determinants for asthma control, quality of life and use of complementary and alternative medicine in asthmatic pediatric patients in four cities.

Authors:  Kam Lun Hon; Yan Min Bao; Kate C Chan; Kin Wai Chau; Rong-Shan Chen; Kun Tat Gary Cheok; Wa Keung Chiu; Li Deng; Chun-Hui He; Kin Mui Ieong; Jeng Sum C Kung; Ping Lam; Shu Yan David Lam; Qun Ui Lee; So Lun Lee; Ting Fan Leung; Theresa N H Leung; Lei Shi; Ka Ka Siu; Wei-Ping Tan; Maggie Haitian Wang; Tak Wai Wong; Bao-Jing Wu; Ada Y F Yip; Yue-Jie Zheng; Daniel K Ng
Journal:  World J Pediatr       Date:  2018-07-25       Impact factor: 2.764

4.  Emodin alleviates alternatively activated macrophage and asthmatic airway inflammation in a murine asthma model.

Authors:  Yun-Duan Song; Xiao-Zong Li; Ya-Xian Wu; Yao Shen; Fang-Fang Liu; Pei-Pei Gao; Lei Sun; Feng Qian
Journal:  Acta Pharmacol Sin       Date:  2018-02-08       Impact factor: 6.150

5.  Majie cataplasm provides a shield against asthmatic punch from the neuroimmune system.

Authors:  Wenting Ji; Xue Yu; Yushan Gao; Beida Ren; Shuang Zhang; Qingguo Wang; Xueqian Wang
Journal:  Heliyon       Date:  2020-05-23

6.  A multicenter, prospective, observational study on montelukast monotherapy or montelukast-based combinations treating cough variant asthma.

Authors:  Jiangtao Lin; Zaiyi Wang; Chen Qiu; Zhen Wang; Shanping Jiang; Huaping Tang; Xuefen Wang; Zhongmin Qiu; Yong He; Jianping Zhao; Guochao Shi; Shenghua Sun; Limin Wang; Lin Chen; Jue Wang; Annhua Mao
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.